- 2024-31 Core income statement and product revenue figures are as at 07/06/2024
- Q2 2024 Core income statement and product revenue figures are as at 24/07/2024
£m (unless stated) | Q2'24 | Q2'24 n= | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2024-2028 n= |
---|---|---|---|---|---|---|---|---|---|---|---|
Turnover - Vaccines ex pandemic solutions | 2,203 | 15 | 10,491 | 11,500 | 12,436 | 13,033 | 13,295 | 13,647 | 14,017 | 14,059 | 15 |
Turnover - Specialty ex pandemic solutions | 2,860 | 15 | 11,446 | 12,455 | 13,484 | 14,472 | 14,542 | 14,511 | 13,844 | 12,903 | 15 |
Turnover - General Medicines | 2,445 | 15 | 9,680 | 9,607 | 9,572 | 9,323 | 8,944 | 8,635 | 8,026 | 7,307 | 15 |
Turnover - GSK excluding pandemic solutions | 7,508 | 15 | 31,616 | 33,561 | 35,492 | 36,828 | 36,781 | 36,793 | 35,887 | 34,269 | 15 |
Turnover - pandemic solutions | - | 15 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
Turnover - GSK | 7,508 | 15 | 31,617 | 33,561 | 35,492 | 36,828 | 36,781 | 36,793 | 35,887 | 34,269 | 15 |
Cost of sales | (1,797) | 15 | (7,839) | (8,211) | (8,595) | (8,872) | (8,969) | (9,092) | (8,999) | (8,631) | 15 |
Selling, general and administration | (2,224) | 15 | (9,139) | (9,471) | (9,798) | (10,055) | (10,056) | (10,173) | (10,112) | (9,869) | 15 |
Research and Development | (1,384) | 15 | (6,020) | (6,272) | (6,533) | (6,748) | (6,775) | (6,848) | (6,828) | (6,710) | 15 |
Royalty income | 136 | 15 | 571 | 594 | 643 | 627 | 527 | 513 | 517 | 467 | 15 |
Operating profit | 2,239 | 15 | 9,189 | 10,201 | 11,209 | 11,780 | 11,508 | 11,195 | 10,466 | 9,527 | 15 |
Net finance costs | (145) | 15 | (594) | (536) | (508) | (461) | (402) | (359) | (310) | (256) | 15 |
Associates | - | 15 | (2) | (2) | (2) | (2) | (2) | (2) | (2) | (3) | 15 |
Profit before tax | 2,094 | 15 | 8,593 | 9,664 | 10,700 | 11,317 | 11,104 | 10,834 | 10,154 | 9,269 | 15 |
Taxation | (356) | 15 | (1,458) | (1,659) | (1,846) | (1,961) | (1,925) | (1,868) | (1,753) | (1,594) | 15 |
Tax Rate | 17% | 15 | 17.0% | 17.2% | 17.2% | 17.3% | 17.3% | 17.2% | 17.3% | 17.2% | 15 |
Profit after tax | 1,738 | 15 | 7,136 | 8,004 | 8,854 | 9,356 | 9,179 | 8,966 | 8,401 | 7,675 | 15 |
Minority interests | (152) | 15 | (636) | (672) | (703) | (726) | (666) | (595) | (493) | (361) | 15 |
Profit attributable to shareholders | 1,586 | 15 | 6,499 | 7,332 | 8,152 | 8,630 | 8,513 | 8,371 | 7,909 | 7,314 | 15 |
WANS (m) | 4,077 | 15 | 4,070 | 4,088 | 4,104 | 4,115 | 4,117 | 4,112 | 4,110 | 4,107 | 15 |
Earnings per share (p) | 38.9 | 15 | 159.7 | 179.4 | 198.6 | 209.7 | 206.7 | 203.5 | 192.7 | 179.1 | 15 |
Dividend per share (p) | 15.0 | 10 | 60.0 | 62.1 | 64.3 | 66.1 | 68.0 | 69.0 | 69.3 | 69.1 | 14 |
Free Cash Flow | n/a | n/a | 4,953 | 6,097 | 6,919 | 7,293 | 7,180 | 7,244 | 7,097 | 6,826 | 12 |
Net Debt | n/a | n/a | (12,020) | (8,742) | (4,756) | (640) | 3,185 | 7,356 | 11,105 | 15,838 | 12 |
USD / GBP | 1.26 | 15 | 1.26 | 1.26 | 1.26 | 1.26 | 1.26 | 1.26 | 1.26 | 1.26 | 15 |
EUR / GBP | 1.17 | 14 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 14 |
JPY / GBP | 196 | 11 | 191 | 193 | 193 | 193 | 193 | 193 | 193 | 193 | 11 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, TD Cowen, Deutsche Bank, BNP Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn Atlantic , UBS, Wolfe Research
Turnover £m | Q2'24 | Q2'24 n= | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2024-2028 n= |
---|---|---|---|---|---|---|---|---|---|---|---|
Shingrix | 1,036 | 15 | 3,929 | 4,435 | 4,862 | 4,974 | 5,002 | 5,060 | 5,033 | 4,908 | 15 |
Arexvy | 70 | 15 | 1,543 | 1,956 | 2,341 | 2,639 | 2,638 | 2,685 | 2,804 | 2,726 | 15 |
Bexsero | 203 | 15 | 880 | 900 | 909 | 914 | 920 | 911 | 917 | 902 | 15 |
Menveo | 70 | 15 | 402 | 406 | 408 | 408 | 410 | 405 | 407 | 392 | 15 |
Other Meningitis | 6 | 9 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 27 | 9 |
Meningitis | 279 | 15 | 1,311 | 1,335 | 1,346 | 1,351 | 1,359 | 1,345 | 1,353 | 1,321 | 15 |
Fluarix/Flulaval | 21 | 15 | 468 | 458 | 451 | 446 | 441 | 437 | 434 | 424 | 15 |
Boostrix | 163 | 14 | 614 | 621 | 627 | 633 | 639 | 639 | 645 | 642 | 15 |
Cervarix | 44 | 13 | 117 | 116 | 116 | 115 | 114 | 112 | 111 | 116 | 14 |
Hepatitis | 164 | 14 | 632 | 652 | 665 | 675 | 686 | 691 | 701 | 697 | 15 |
Infanrix, Pediarix | 84 | 14 | 522 | 518 | 515 | 514 | 513 | 513 | 513 | 508 | 15 |
Priorix | 55 | 8 | 284 | 285 | 286 | 287 | 287 | 288 | 288 | 264 | 9 |
Rotarix | 180 | 14 | 616 | 627 | 633 | 640 | 646 | 651 | 657 | 654 | 15 |
Synflorix | 67 | 14 | 243 | 227 | 216 | 209 | 203 | 198 | 194 | 180 | 15 |
Established Vaccines | 797 | 15 | 3,233 | 3,246 | 3,251 | 3,264 | 3,279 | 3,276 | 3,293 | 3,260 | 15 |
Other Vaccines pipeline | - | 15 | 7 | 69 | 185 | 360 | 576 | 844 | 1,100 | 1,420 | 15 |
Vaccines ex pandemic solutions | 2,203 | 15 | 10,491 | 11,500 | 12,436 | 13,033 | 13,295 | 13,647 | 14,017 | 14,059 | 15 |
Pandemic solutions | - | 15 | - | - | - | - | - | - | - | - | 15 |
Vaccines | 2,203 | 15 | 10,491 | 11,500 | 12,436 | 13,033 | 13,295 | 13,647 | 14,017 | 14,059 | 15 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, TD Cowen, Deutsche Bank, BNP Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn Atlantic , UBS, Wolfe Research
Turnover £m | Q2'24 | Q2'24 n= | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2024-2028 n= |
---|---|---|---|---|---|---|---|---|---|---|---|
Tivicay | 313 | 13 | 1,282 | 1,137 | 1,022 | 918 | 626 | 416 | 305 | 214 | 13 |
Triumeq | 329 | 13 | 1,290 | 1,091 | 935 | 808 | 487 | 294 | 199 | 127 | 13 |
Juluca | 167 | 15 | 680 | 680 | 683 | 687 | 646 | 552 | 372 | 189 | 15 |
Dovato | 513 | 15 | 2,147 | 2,364 | 2,521 | 2,603 | 2,440 | 2,051 | 1,079 | 731 | 15 |
Dolutegravir based regimens | 1,322 | 15 | 5,399 | 5,273 | 5,160 | 5,016 | 4,199 | 3,314 | 1,956 | 1,261 | 15 |
Cabenuva | 256 | 15 | 1,044 | 1,332 | 1,581 | 1,786 | 1,945 | 2,100 | 2,187 | 1,737 | 15 |
Apretude | 69 | 15 | 305 | 470 | 631 | 765 | 880 | 957 | 980 | 811 | 15 |
Cabotegravir based regimens | 325 | 15 | 1,348 | 1,802 | 2,212 | 2,551 | 2,825 | 3,057 | 3,167 | 2,548 | 15 |
Rukobia | 34 | 15 | 144 | 162 | 175 | 186 | 190 | 199 | 183 | 163 | 15 |
Other HIV (including pipeline) | 13 | 15 | 48 | 39 | 39 | 75 | 132 | 201 | 331 | 551 | n/a |
HIV | 1,694 | 15 | 6,939 | 7,275 | 7,587 | 7,827 | 7,346 | 6,771 | 5,637 | 4,524 | 15 |
Benlysta | 400 | 15 | 1,477 | 1,581 | 1,620 | 1,607 | 1,564 | 1,472 | 1,349 | 1,292 | 15 |
Nucala | 459 | 15 | 1,800 | 1,910 | 1,960 | 1,946 | 1,775 | 1,594 | 1,435 | 1,248 | 15 |
Zejula | 140 | 15 | 586 | 637 | 691 | 740 | 758 | 748 | 718 | 348 | 15 |
Blenrep | 3 | 15 | 14 | 66 | 206 | 348 | 492 | 664 | 778 | 925 | 15 |
Jemperli | 89 | 15 | 348 | 468 | 552 | 617 | 665 | 700 | 725 | 728 | 15 |
Ojjaara | 66 | 15 | 249 | 410 | 562 | 701 | 806 | 889 | 961 | 1,014 | 15 |
Other Oncology (including pipeline) | - | 15 | 1 | 2 | 16 | 46 | 74 | 117 | 153 | 153 | n/a |
Oncology | 298 | 15 | 1,198 | 1,584 | 2,027 | 2,452 | 2,795 | 3,119 | 3,335 | 3,168 | 15 |
camlipixant | - | - | - | - | 34 | 104 | 182 | 275 | 370 | 451 | 14 |
daprodustat | - | - | 21 | 43 | 58 | 70 | 81 | 93 | 98 | 99 | 15 |
depemokimab | - | - | - | 47 | 171 | 333 | 502 | 664 | 806 | 967 | 14 |
Specialty Medicines ex pandemic solutions | 2,860 | 15 | 11,446 | 12,455 | 13,484 | 14,472 | 14,542 | 14,511 | 13,844 | 12,903 | 15 |
Xevudy | - | 15 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
Specialty Medicines | 2,860 | 15 | 11,446 | 12,455 | 13,484 | 14,472 | 14,542 | 14,511 | 13,844 | 12,903 | 15 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, TD Cowen, Deutsche Bank, BNP Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn Atlantic , UBS, Wolfe Research
Turnover £m | Q2'24 | Q2'24 n= | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2024-2028 n= |
---|---|---|---|---|---|---|---|---|---|---|---|
Anoro | 134 | 15 | 539 | 535 | 532 | 520 | 497 | 459 | 399 | 346 | 15 |
Flixotide/Flovent | 76 | 15 | 346 | 305 | 285 | 267 | 252 | 231 | 218 | 217 | 15 |
Relvar/Breo | 269 | 15 | 1,039 | 1,024 | 1,009 | 953 | 868 | 780 | 691 | 592 | 15 |
Seretide/Advair | 236 | 15 | 924 | 818 | 737 | 669 | 614 | 567 | 525 | 498 | 15 |
Trelegy | 692 | 15 | 2,571 | 2,825 | 3,014 | 3,015 | 2,892 | 2,787 | 2,444 | 2,012 | 15 |
Ventolin | 150 | 15 | 649 | 612 | 581 | 552 | 526 | 507 | 487 | 462 | 15 |
Other respiratory | 144 | 15 | 544 | 521 | 497 | 474 | 433 | 391 | 336 | 301 | 15 |
Respiratory | 1,701 | 14 | 6,612 | 6,641 | 6,654 | 6,450 | 6,082 | 5,722 | 5,100 | 4,428 | 15 |
Augmentin | 129 | 13 | 621 | 615 | 601 | 586 | 571 | 567 | 553 | 547 | 14 |
Lamictal | 81 | 12 | 330 | 299 | 273 | 255 | 240 | 224 | 211 | 205 | 13 |
Other Other General Medicines | 534 | 12 | 2,116 | 2,052 | 2,043 | 2,032 | 2,051 | 2,123 | 2,162 | 2,128 | n/a |
Other General Medicines | 744 | 14 | 3,068 | 2,966 | 2,918 | 2,873 | 2,861 | 2,913 | 2,926 | 2,880 | 15 |
General Medicines | 2,445 | 15 | 9,680 | 9,607 | 9,572 | 9,323 | 8,944 | 8,635 | 8,026 | 7,307 | 15 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, TD Cowen, Deutsche Bank, BNP Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn Atlantic , UBS, Wolfe Research